Physician profile
Michael Durando
NPI 1750776910
$2,496.46
in general payments reported to CMS, 2019-2025
15 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $27.94 · 2022: $123 · 2023: $1,107 · 2024: $970 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,975 · Food and Beverage: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,975.00 |
| Food and Beverage | $235.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Global Services, LLC | $1,050.00 | 2023 | Erleada |
| Astrazeneca Pharmaceuticals LP | $939.70 | 2022-2024 | Truqap, Imfinzi |
| Karyopharm Therapeutics INC. | $133.74 | 2025 | Xpovio |
| Genzyme Corporation | $114.95 | 2019 | |
| Tersera Therapeutics LLC | $35.05 | 2023 | Zoladex |
| Pfizer INC. | $33.26 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.64 | 2022 | |
| Sobi, INC | $30.06 | 2022 | |
| Eisai INC. | $26.80 | 2024 | |
| Servier Pharmaceuticals LLC | $21.86 | 2023 | |
| Daiichi Sankyo INC. | $19.09 | 2022 | |
| Puma Biotechnology, INC. | $18.40 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $16.41 | 2022 | |
| Verastem, INC. | $14.44 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Durando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.